Immunotherapy: 424 Real Stories

424 stories match immunotherapy. 352 of them mention chemotherapy.

Cancer Stories

Eutha, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Eutha's Survivor Story

Patient Info: Eutha, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

Eutha completed clinical-trial immunotherapy, right mastectomy with lymph-node removal, chemotherapy, radiation and reconstruction for Stage II ER-positive, PR-positive, HER2-positive breast cancer, and returned to work and community life; no explicit NED/cancer-free status was provided.

Memorial Sloan Kettering
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage II Lung Squamous Cell CarcinomaLung Cancer

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Durable complete remission after brain metastases from gastric cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: HER2-low, PD-L1 CPS 5

Metastatic Site: brain

By July 2024 the brain lesions had completely resolved, and complete remission remained sustained through October 2025, with more than 38 months off anticancer treatment.

PubMed Central
OutcomeCancer-Free / NED
Cindy, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV MSI-High Colorectal Cancer: Cindy's Patient Story

Patient Info: Cindy Mette, Female | Stage IV

Biomarkers: MSI-high

Cindy’s tumor responded to the experimental Werner helicase inhibitor, with falling CEA levels and radiologic response. The response was continuing in 2025 while she remained on the clinical trial.

MD Anderson
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Lung Squamous Cell CarcinomaLung Cancer

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Long-term lung cancer control after immunotherapy-related diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 80%; EGFR, ALK, ROS1 and BRAF negative

Metastatic Site: brain|liver

After years of disease control off pembrolizumab, a new brain lesion appeared in December 2025 and was treated with focused radiation. He remained clinically stable under oncology follow-up.

PubMed Central
OutcomeLiving With Cancer
JJ, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV MSI-High Colorectal Cancer: JJ's Patient Story

Patient Info: JJ, Male, Under 40 | Stage IV

Biomarkers: Lynch syndrome; microsatellite instability

Metastatic Site: Abdominal wall; lymph nodes throughout the body

At the latest scan, the main abdominal tumor remained stable. JJ had completed 126 rounds of chemo-immunotherapy and continued treatment every 3 weeks; small lung nodules were being watched but were not confirmed as metastases.

The Patient Story
OutcomeStable Disease / Ongoing Therapy
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed Central
OutcomeResponding Well
Jackie, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Jackie's Patient Story

Patient Info: Jackie, Female | Stage IV

Biomarkers: Lynch syndrome

Metastatic Site: Not reported

Jackie’s Stage IIIB rectal cancer later recurred as Stage IV/metastatic disease, but early immunotherapy response was strong, with no visible tumor on MD Anderson sigmoid scope about 6 weeks after starting treatment.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage IVA lung squamous cell carcinoma with immune-checkpoint-inhibitor-associated Graves thyroid storm

Patient Info: Anonymized, Male | Stage IV

Biomarkers: Cancer biomarkers not reported. Thyroid storm workup had TSAb/TRAb positivity consistent with Graves disease.

Metastatic Site: not specified in extracted case text

After thyroid storm improved with antithyroid therapy and supportive care, the patient was transferred for further lung-cancer treatment but died of progressive lung cancer about 2 months later.

PubMed Central
OutcomeIn Memory
Hugo, who was diagnosed with Stage I Colorectal CancerColorectal Cancer

Stage I Colorectal Cancer: Hugo's Patient Story

Patient Info: Hugo, Male, Under 40 | Stage I

As of June 2026, Hugo had no active cancer after subtotal colectomy, but care remained ongoing with infusions every 6-8 weeks for bowel inflammation and high recurrence risk.

The Patient Story
OutcomeCare Ongoing